Evommune Statistics
Total Valuation
Evommune has a market cap or net worth of $515.71 million. The enterprise value is $323.55 million.
| Market Cap | 515.71M |
| Enterprise Value | 323.55M |
Important Dates
The last earnings date was Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Evommune has 36.29 million shares outstanding. The number of shares has increased by 1,390.45% in one year.
| Current Share Class | 36.29M |
| Shares Outstanding | 36.29M |
| Shares Change (YoY) | +1,390.45% |
| Shares Change (QoQ) | +7.32% |
| Owned by Insiders (%) | 2.50% |
| Owned by Institutions (%) | 63.26% |
| Float | 19.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 50.30 |
| Forward PS | 140.84 |
| PB Ratio | 1.84 |
| P/TBV Ratio | 1.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 31.08 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.68, with a Debt / Equity ratio of 0.03.
| Current Ratio | 11.68 |
| Quick Ratio | 11.48 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -52.11% and return on invested capital (ROIC) is -34.17%.
| Return on Equity (ROE) | -52.11% |
| Return on Assets (ROA) | -31.99% |
| Return on Invested Capital (ROIC) | -34.17% |
| Return on Capital Employed (ROCE) | -35.82% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $208,333 |
| Profits Per Employee | -$1.97M |
| Employee Count | 48 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 15.89 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 54.54 |
| Average Volume (20 Days) | 563,871 |
Short Selling Information
The latest short interest is 4.02 million, so 11.07% of the outstanding shares have been sold short.
| Short Interest | 4.02M |
| Short Previous Month | 4.27M |
| Short % of Shares Out | 11.07% |
| Short % of Float | 20.86% |
| Short Ratio (days to cover) | 2.86 |
Income Statement
In the last 12 months, Evommune had revenue of $10.00 million and -$94.67 million in losses. Loss per share was -$4.15.
| Revenue | 10.00M |
| Gross Profit | 10.00M |
| Operating Income | -101.89M |
| Pretax Income | -94.67M |
| Net Income | -94.67M |
| EBITDA | -100.36M |
| EBIT | -101.89M |
| Loss Per Share | -$4.15 |
Balance Sheet
The company has $200.79 million in cash and $8.63 million in debt, with a net cash position of $192.16 million or $5.29 per share.
| Cash & Cash Equivalents | 200.79M |
| Total Debt | 8.63M |
| Net Cash | 192.16M |
| Net Cash Per Share | $5.29 |
| Equity (Book Value) | 277.59M |
| Book Value Per Share | 7.65 |
| Working Capital | 186.76M |
Cash Flow
In the last 12 months, operating cash flow was -$74.15 million and capital expenditures -$501,000, giving a free cash flow of -$74.65 million.
| Operating Cash Flow | -74.15M |
| Capital Expenditures | -501,000 |
| Depreciation & Amortization | 1.54M |
| Net Borrowing | -451,000 |
| Free Cash Flow | -74.65M |
| FCF Per Share | -$2.06 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,018.94% |
| Pretax Margin | -946.68% |
| Profit Margin | n/a |
| EBITDA Margin | -1,003.55% |
| EBIT Margin | -1,018.93% |
| FCF Margin | n/a |
Dividends & Yields
Evommune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,390.45% |
| Shareholder Yield | -1,390.45% |
| Earnings Yield | -18.82% |
| FCF Yield | -14.84% |
Analyst Forecast
The average price target for Evommune is $27.57, which is 94.02% higher than the current price. The consensus rating is "Buy".
| Price Target | $27.57 |
| Price Target Difference | 94.02% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | -48.75% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evommune has an Altman Z-Score of 16.62 and a Piotroski F-Score of 2.
| Altman Z-Score | 16.62 |
| Piotroski F-Score | 2 |